Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

[New endoscopic methods: hemostasis by over-the-scope clip (OTSC) and endoscopic full-thickness resection with the Full Thickness Resection Device (FTRD)].

Meier A, Eigler A.

MMW Fortschr Med. 2018 Jun;160(12):61-64. doi: 10.1007/s15006-018-0710-y. Review. German. No abstract available.

PMID:
29943006
2.

Meningeal spread of blastic plasmacytoid dendritic cell neoplasm.

Starck M, Zewen S, Eigler A, Wendtner CM.

Eur J Haematol. 2014 Aug;93(2):175-6. doi: 10.1111/ejh.12280. Epub 2014 Feb 26. No abstract available.

PMID:
24483771
3.

Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.

Bauer C, Sterzik A, Bauernfeind F, Duewell P, Conrad C, Kiefl R, Endres S, Eigler A, Schnurr M, Dauer M.

Cancer Immunol Immunother. 2014 Apr;63(4):321-33. doi: 10.1007/s00262-013-1510-y. Epub 2014 Jan 3.

PMID:
24384835
4.

The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.

Rieder F, Siegmund B, Bundschuh DS, Lehr HA, Endres S, Eigler A.

PLoS One. 2013;8(2):e56867. doi: 10.1371/journal.pone.0056867. Epub 2013 Feb 28.

5.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, Morelli AB, Clausen BE, Dauer M, Eigler A, Anz D, Bourquin C, Maraskovsky E, Endres S, Schnurr M.

J Immunol. 2011 Jul 1;187(1):55-63. doi: 10.4049/jimmunol.1004114. Epub 2011 May 25.

6.

Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.

Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Oduncu F, Emmerich B, Mayr D, Mussack T, Bruns C, Rüttinger D, Conrad C, Jauch KW, Endres S, Eigler A.

Cancer Immunol Immunother. 2011 Aug;60(8):1097-107. doi: 10.1007/s00262-011-1023-5. Epub 2011 May 6.

PMID:
21547597
7.

An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma.

Jacobs C, Duewell P, Heckelsmiller K, Wei J, Bauernfeind F, Ellermeier J, Kisser U, Bauer CA, Dauer M, Eigler A, Maraskovsky E, Endres S, Schnurr M.

Int J Cancer. 2011 Feb 15;128(4):897-907. doi: 10.1002/ijc.25399.

8.

Dendritic cell-based cancer vaccination: quo vadis?

Dauer M, Schnurr M, Eigler A.

Expert Rev Vaccines. 2008 Sep;7(7):1041-53. doi: 10.1586/14760584.7.7.1041. Review.

PMID:
18767953
9.

Combined use of toll-like receptor agonists and prostaglandin E(2) in the FastDC model: rapid generation of human monocyte-derived dendritic cells capable of migration and IL-12p70 production.

Dauer M, Lam V, Arnold H, Junkmann J, Kiefl R, Bauer C, Schnurr M, Endres S, Eigler A.

J Immunol Methods. 2008 Sep 15;337(2):97-105. doi: 10.1016/j.jim.2008.07.003. Epub 2008 Jul 25.

PMID:
18657542
10.

Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.

Bauer C, Bauernfeind F, Sterzik A, Orban M, Schnurr M, Lehr HA, Endres S, Eigler A, Dauer M.

Gut. 2007 Sep;56(9):1275-82. Epub 2007 Mar 29.

11.

The ICE inhibitor pralnacasan prevents DSS-induced colitis in C57BL/6 mice and suppresses IP-10 mRNA but not TNF-alpha mRNA expression.

Bauer C, Loher F, Dauer M, Mayer C, Lehr HA, Schönharting M, Hallwachs R, Endres S, Eigler A.

Dig Dis Sci. 2007 Jul;52(7):1642-52. Epub 2007 Mar 28.

PMID:
17393315
12.

Vascular ectasia of the whole intestine as a cause of recurrent gastrointestinal bleeding after high-dose chemotherapy.

Schmidmaier R, Bittmann I, Götzberger M, Straka C, Meinhardt G, Eigler A.

Endoscopy. 2006 Sep;38(9):940-2.

PMID:
17019760
13.

Education and imaging. Hepatobiliary and pancreatic: large pancreatic pseudocyst.

Lippl F, Eibel R, Heldwein W, Eigler A.

J Gastroenterol Hepatol. 2006 Oct;21(10):1629. No abstract available.

PMID:
16928231
14.

IFN-alpha promotes definitive maturation of dendritic cells generated by short-term culture of monocytes with GM-CSF and IL-4.

Dauer M, Schad K, Junkmann J, Bauer C, Herten J, Kiefl R, Schnurr M, Endres S, Eigler A.

J Leukoc Biol. 2006 Aug;80(2):278-86. Epub 2006 Jun 12.

PMID:
16769767
15.

Sphingosine kinase and sphingosine-1-phosphate regulate migration, endocytosis and apoptosis of dendritic cells.

Eigenbrod S, Derwand R, Jakl V, Endres S, Eigler A.

Immunol Invest. 2006;35(2):149-65.

PMID:
16698674
16.

Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells.

Dauer M, Herten J, Bauer C, Renner F, Schad K, Schnurr M, Endres S, Eigler A.

J Immunother. 2005 Jul-Aug;28(4):332-42.

PMID:
16000951
17.

FastDC derived from human monocytes within 48 h effectively prime tumor antigen-specific cytotoxic T cells.

Dauer M, Schad K, Herten J, Junkmann J, Bauer C, Kiefl R, Endres S, Eigler A.

J Immunol Methods. 2005 Jul;302(1-2):145-55.

PMID:
15992809
18.

Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes.

Obermaier B, Dauer M, Herten J, Schad K, Endres S, Eigler A.

Biol Proced Online. 2003;5:197-203. Epub 2003 Oct 24.

19.

The interleukin-1 beta-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation.

Loher F, Bauer C, Landauer N, Schmall K, Siegmund B, Lehr HA, Dauer M, Schoenharting M, Endres S, Eigler A.

J Pharmacol Exp Ther. 2004 Feb;308(2):583-90. Epub 2003 Nov 10.

PMID:
14610233
20.
21.

Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors.

Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, Schnurr M, Endres S, Eigler A.

J Immunol. 2003 Apr 15;170(8):4069-76.

22.

The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice.

Loher F, Schmall K, Freytag P, Landauer N, Hallwachs R, Bauer C, Siegmund B, Rieder F, Lehr HA, Dauer M, Kapp JF, Endres S, Eigler A.

J Pharmacol Exp Ther. 2003 May;305(2):549-56. Epub 2003 Feb 11.

PMID:
12606674
23.

[Drug-induced pancreatitis].

Eigler A, Eigenbrod S, Endres S.

Dtsch Med Wochenschr. 2003 Feb 21;128(8):366-9. Review. German. No abstract available.

PMID:
12594621
24.

Soluble tumor necrosis factor receptor type II in the early diagnosis of fever in neutropenia.

Goetz M, Behre G, Heussel G, Steinmetz HT, Eigler A, Hiddemann W, Weiss M.

Ann Hematol. 2002 Jul;81(7):382-5. Epub 2002 Jun 25.

PMID:
12185508
25.

Determination of thiopurine S-methyltransferase phenotype using thin-layer chromatography and quantitative scanning.

Dauer M, Schulze J, Loher F, Endres S, Eigler A.

Eur J Clin Pharmacol. 2002 Apr;58(1):41-4. Epub 2002 Mar 12.

PMID:
11956672
26.

Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.

Schnurr M, Scholz C, Rothenfusser S, Galambos P, Dauer M, Röbe J, Endres S, Eigler A.

Cancer Res. 2002 Apr 15;62(8):2347-52.

27.

Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.

Siegmund B, Welsch J, Loher F, Meinhardt G, Emmerich B, Endres S, Eigler A.

Leukemia. 2001 Oct;15(10):1564-71.

28.

Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.

Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello CA, Endres S, Eigler A.

Am J Physiol Regul Integr Comp Physiol. 2001 Oct;281(4):R1264-73.

29.
30.

Shock waves: a novel method for cytoplasmic delivery of antisense oligonucleotides.

Tschoep K, Hartmann G, Jox R, Thompson S, Eigler A, Krug A, Erhardt S, Adams G, Endres S, Delius M.

J Mol Med (Berl). 2001 Jun;79(5-6):306-13.

PMID:
11485025
31.

[Suppression of synthesis of tumor necrosis factor].

Eigler A, Loher F, Endres S.

Internist (Berl). 2001 Jan;42(1):28-34. Review. German. No abstract available.

PMID:
11271618
32.

Adenosine kinase inhibitor GP515 improves experimental colitis in mice.

Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, Firestein GS, Boyle D, Lehr HA, Loher F, Hartmann G, Endres S, Eigler A.

J Pharmacol Exp Ther. 2001 Jan;296(1):99-105.

PMID:
11123368
33.

Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo.

Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartmann G, Endres S.

J Immunol. 2000 Dec 1;165(11):6278-86.

34.

Extracellular ATP and TNF-alpha synergize in the activation and maturation of human dendritic cells.

Schnurr M, Then F, Galambos P, Scholz C, Siegmund B, Endres S, Eigler A.

J Immunol. 2000 Oct 15;165(8):4704-9.

35.
36.

Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor.

Eigler A, Matschke V, Hartmann G, Erhardt S, Boyle D, Firestein GS, Endres S.

J Leukoc Biol. 2000 Jul;68(1):97-103.

PMID:
10914495
37.

Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.

Hartmann G, Bidlingmaier C, Siegmund B, Albrich S, Schulze J, Tschoep K, Eigler A, Lehr HA, Endres S.

J Pharmacol Exp Ther. 2000 Jan;292(1):22-30.

PMID:
10604928
38.

Cytokines and therapeutic oligonucleotides.

Hartmann G, Bidlingmaier M, Eigler A, Hacker U, Endres S.

Cytokines Cell Mol Ther. 1997 Dec;3(4):247-56. Review.

PMID:
9740353
39.

Adrenaline enhances LPS-induced IL-10 synthesis: evidence for protein kinase A-mediated pathway.

Siegmund B, Eigler A, Hartmann G, Hacker U, Endres S.

Int J Immunopharmacol. 1998 Jan-Mar;20(1-3):57-69.

PMID:
9717082
40.

The hairy cell leukemia cell line Eskol spontaneously synthesizes tumor necrosis factor-alpha and nitric oxide.

Eigler A, Waller-Fontaine K, Moeller J, Hartmann G, Hacker UT, Endres S.

Leuk Res. 1998 Jun;22(6):501-7.

PMID:
9678716
41.

Nitric oxide downregulates tumour necrosis factor in mRNA in RAW 264.7 cells.

Sinha B, Eigler A, Baumann KH, Greten TF, Moeller J, Endres S.

Res Immunol. 1998 Feb;149(2):139-50.

PMID:
9628395
42.

Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes.

Hartmann G, Krug A, Bidlingmaier M, Hacker U, Eigler A, Albrecht R, Strasburger CJ, Endres S.

J Pharmacol Exp Ther. 1998 May;285(2):920-8.

PMID:
9580645
43.

Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms.

Hacker UT, Bidlingmaier C, Gomolka M, Keller E, Eigler A, Hartmann G, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S.

Eur J Clin Invest. 1998 Mar;28(3):214-9.

PMID:
9568467
44.

In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination.

Hacker UT, Jelinek T, Erhardt S, Eigler A, Hartmann G, Nothdurft HD, Endres S.

J Infect Dis. 1998 Mar;177(3):774-8.

PMID:
9498462
45.

Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.

Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S.

J Leukoc Biol. 1998 Jan;63(1):101-7.

PMID:
9469479
46.

[Therapy with anti-TNF antibodies in patients with Crohn disease].

Eigler A, Endres S.

Z Gastroenterol. 1997 Sep;35(9):899-901. German. No abstract available.

PMID:
9432823
47.

Taming TNF: strategies to restrain this proinflammatory cytokine.

Eigler A, Sinha B, Hartmann G, Endres S.

Immunol Today. 1997 Oct;18(10):487-92. Review.

PMID:
9357141
48.

[Inhibition of nitric oxide synthase in septic shock. Therapeutic limits and perspectives].

Endres S, Eigler A.

Internist (Berl). 1997 May;38(5):466-9. Review. German. No abstract available.

PMID:
9264984
49.

Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis.

Hacker UT, Gomolka M, Keller E, Eigler A, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S.

Gut. 1997 May;40(5):623-7.

50.

Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents.

Siegmund B, Eigler A, Moeller J, Greten TF, Hartmann G, Endres S.

Eur J Pharmacol. 1997 Feb 26;321(2):231-9.

PMID:
9063693

Supplemental Content

Loading ...
Support Center